Federal grand jury indicts California company in alleged $100 million Adderall scheme

A federal grand jury in San Francisco indicted California-based Done Global Inc. and Florida practice Mindful Mental Wellness P.A. for an alleged years-long telehealth scheme that illegally distributed Adderall and other stimulants, reportedly generating over $100 million and providing access to more than 40 million pills. Charges against Done Global include conspiracy to illegally distribute controlled substances, four counts of illegal distribution, conspiracy to commit health care fraud and conspiracy to obstruct justice; potential penalties include disgorgement up to twice gross profits or proceeds. The action signals heightened criminal and regulatory risk for digital health/telehealth operators and could materially impair Done Global’s valuation and investor sentiment in the sector if convictions follow.

Analysis

Market structure: The indictment is an acute negative shock to pure‑play telehealth and prescription‑fulfillment chains that monetized high‑velocity stimulant scripts; expect reputational hits and patient-volume declines for small/venture telehealth platforms (e.g., AMWL, HIMS, RO) and higher compliance sourcing for pharmacies (CVS, WBA). Incumbent integrated players with strong compliance and PBM relationships should gain share and pricing leverage as insurers and state Medicaid programs tighten credentialing and prior‑authorization — a 3–12 month window for share reallocation is likely.

Risk assessment: Tail risk includes a DOJ/DOH sweep across telehealth that could force multi‑billion dollar settlements and industrywide stricter DEA/CMS oversight; low‑probability but high‑impact (10–30% sector revenue hit) over 6–24 months. Near term (days–weeks) expect headline volatility and idiosyncratic downdrafts; medium term (3–9 months) watch for new federal guidance/regulations and subpoena cascades; hidden dependencies include payment processors, ad networks and subscription revenue models that can evaporate quickly.

Trade implications: Favor long positions in large compliant health‑care operators (CVS, WBA) and shorts or protected exposure to small telehealth/software names (AMWL, HIMS, RO) over 3–9 months. Use put spreads on highly exposed tickers to limit premium spend; tilt sector rotation into insurers and PBMs and out of subscription telehealth where EBITDA was driven by questionable prescribing.

Contrarian angles: The market may over‑penalize all telehealth — high‑quality telemedicine franchises (TDOC) that derive <25% revenue from controlled substances could be mispriced; historical parallel: opioid telemarketing crackdown redistributed market share to compliant incumbents and produced 12–24 month mean reversion. If DOJ confines enforcement to a few actors, small‑cap telehealth selloff could be a buying opportunity once regulatory language clarifies eligibility (monitor next 30–90 days).

Key Decisions for Investors

• Establish a 2–3% portfolio short position in small/volatile telehealth equities: Amwell (AMWL) and Hims & Hers (HIMS) combined (1–1.5% each) via equity or buy 3‑month 15–25% OTM put spreads; target 25–40% downside in 3–6 months, cut loss if position moves against by 30% or if DOJ guidance limits scope to private actors within 30 days.
• Initiate a 2–4% long position in integrated pharmacy/healthcare operators: CVS Health (CVS) or Walgreens (WBA) to capture share shift and compliance premium; hold 6–12 months, target 12–18% upside, trim if quarterly script growth <1% YoY or if material regulatory fines exceed $1B for sector incumbents.
• Deploy a hedged options strategy on larger telehealth: buy 3–6 month puts (10–20% OTM) on Teladoc (TDOC) sized at 0.5–1% equity exposure funded by selling 1–2 month calls to collect premium; objective is protection against headlines while limiting premium outlay, exit on clarity of regulatory scope within 60–90 days.
• Short 0.5–1% exposure to consumer digital‑health subscription names (RO) via buy‑write or put spreads; if DOJ enforcement expands to name platforms or payment processors in next 30–90 days, increase shorts to 2–3% and rotate proceeds into PBM/insurer ETFs (e.g., IBB/HMO/XLV) for 6–12 month hold.